CN102081101B - 用于在急性中风或暂时性缺血性发作的患者中诊断细菌感染和指导抗生素治疗的降钙素原 - Google Patents

用于在急性中风或暂时性缺血性发作的患者中诊断细菌感染和指导抗生素治疗的降钙素原 Download PDF

Info

Publication number
CN102081101B
CN102081101B CN201010510497.3A CN201010510497A CN102081101B CN 102081101 B CN102081101 B CN 102081101B CN 201010510497 A CN201010510497 A CN 201010510497A CN 102081101 B CN102081101 B CN 102081101B
Authority
CN
China
Prior art keywords
stroke
application
procalcitonin
patients
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201010510497.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102081101A (zh
Inventor
安德烈亚斯·贝格曼
奥利弗·哈特曼
弗劳克·海因
比特·穆勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pisa
Original Assignee
University of Pisa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41362428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102081101(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Pisa filed Critical University of Pisa
Publication of CN102081101A publication Critical patent/CN102081101A/zh
Application granted granted Critical
Publication of CN102081101B publication Critical patent/CN102081101B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201010510497.3A 2009-10-13 2010-10-13 用于在急性中风或暂时性缺血性发作的患者中诊断细菌感染和指导抗生素治疗的降钙素原 Active CN102081101B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09012947.9 2009-10-13
EP09012947 2009-10-13

Publications (2)

Publication Number Publication Date
CN102081101A CN102081101A (zh) 2011-06-01
CN102081101B true CN102081101B (zh) 2014-08-20

Family

ID=41362428

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201010510497.3A Active CN102081101B (zh) 2009-10-13 2010-10-13 用于在急性中风或暂时性缺血性发作的患者中诊断细菌感染和指导抗生素治疗的降钙素原

Country Status (5)

Country Link
US (1) US8383332B2 (cg-RX-API-DMAC7.html)
EP (1) EP2320237B1 (cg-RX-API-DMAC7.html)
JP (2) JP5722587B2 (cg-RX-API-DMAC7.html)
CN (1) CN102081101B (cg-RX-API-DMAC7.html)
ES (1) ES2601104T3 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE533061T1 (de) * 2007-08-03 2011-11-15 Brahms Gmbh Verfahren zur diagnose bakterieller infektionen
ES2601104T3 (es) * 2009-10-13 2017-02-14 B.R.A.H.M.S Gmbh Procalcitonina para el diagnóstico de infecciones bacterianas y la guía del tratamiento antibiótico en pacientes con apoplejía aguda o accidente isquémico transitorio
ITRM20100121A1 (it) * 2010-03-18 2011-09-19 Univ Pisa Marcatori molecolari per infezioni delle vie urinarie.
CN102305858B (zh) * 2011-07-26 2013-08-21 深圳市国赛生物技术有限公司 一种检测降钙素原的试剂盒
AU2013217935B2 (en) 2012-02-09 2018-05-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
RU2730836C2 (ru) 2014-08-14 2020-08-26 Мемед Диагностикс Лтд. Вычислительный анализ биологических данных с применением многообразия и гиперплоскости
EP3230740B1 (en) 2014-12-11 2025-05-21 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof
CA2992343A1 (en) * 2015-07-13 2017-01-19 University Of Geneva Biomarker panels for brain injury complications
CA3015046A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
EP3440467B1 (en) * 2016-04-08 2020-05-13 Lunginnov Method for diagnosing postoperative pulmonary infections in patients who underwent surgery
CN107490679A (zh) * 2016-06-09 2017-12-19 常州博闻迪医药科技有限公司 一种唾液降钙素原酶联免疫检测方法
CN107490683A (zh) * 2016-06-09 2017-12-19 常州博闻迪医药科技有限公司 一种唾液降钙素原胶体金检测方法
WO2018011795A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018011796A1 (en) * 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
WO2018114044A1 (en) * 2016-12-22 2018-06-28 University Of Geneva Biomarker panels for brain injury complications
EP3438668A1 (en) 2017-08-04 2019-02-06 B.R.A.H.M.S GmbH Diagnosis and risk stratification of fungal infections
JP7366007B2 (ja) 2017-09-13 2023-10-20 ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング プロアドレノメジュリンに基づく輸液療法のガイダンスのための方法
EP3682247B1 (en) 2017-09-13 2022-02-09 B.R.A.H.M.S GmbH Proadrenomedullin as a marker for abnormal platelet levels
EP3502706A1 (en) 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin
WO2019122088A1 (en) * 2017-12-20 2019-06-27 B.R.A.H.M.S Gmbh Antibiotic therapy guidance based on procalcitonin in patients with comorbidities
JP7344208B2 (ja) 2017-12-20 2023-09-13 ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング pro-ADMに基づく抗生物質療法の指導
EP3578989A1 (en) 2018-06-06 2019-12-11 B.R.A.H.M.S GmbH Pro-adm for prognosis of trauma-related complications in polytrauma patients
WO2021083872A1 (en) 2019-10-28 2021-05-06 F. Hoffmann-La Roche Ag Sepsis management
KR102362951B1 (ko) * 2020-08-13 2022-02-14 연세대학교 원주산학협력단 프로칼시토닌 대 c­반응성 단백질의 비율을 이용한 허혈성 뇌졸중의 단기 사망률 예측 방법
JP2024516679A (ja) 2021-04-30 2024-04-16 エフ. ホフマン-ラ ロシュ アーゲー 敗血症の早期検出用のigfbp7マーカーパネル
CN117255947A (zh) 2021-04-30 2023-12-19 豪夫迈·罗氏有限公司 用于脓毒症的早期检测的sFlt1标志物组
CN117255948A (zh) 2021-04-30 2023-12-19 豪夫迈·罗氏有限公司 用于脓毒症的早期检测的pct标志物组
EP4330684A2 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Gdf15 marker panels for early detection of sepsis
WO2026013199A1 (en) 2024-07-12 2026-01-15 Cezanne S.A.S. Clinical immunoassay with early signal measurement

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993811A (en) * 1997-02-03 1999-11-30 Biology Associates, Llc Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
CN101029897A (zh) * 2007-02-09 2007-09-05 深圳市新产业生物医学工程有限公司 一种降钙素原测试试剂盒及其测试方法
EP2032992B1 (en) * 2007-02-28 2009-08-26 B.R.A.H.M.S. Aktiengesellschaft Method for the selective determination of procalcitonin 1-116 for diagnostic purposes and antibodies and kits for carrying out such a method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3147470A1 (de) 1981-12-01 1983-07-14 Bizerba-Werke Wilhelm Kraut GmbH & Co KG, 7460 Balingen Kraftmessvorrichtung
DE19600875C1 (de) * 1996-01-12 1997-06-26 Brahms Diagnostica Gmbh Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
DE112004001863T5 (de) * 2003-10-03 2006-09-07 Scantibodies Laboratory, Inc., Santee Verfahren und Verwendung von Bindungskomponenten zur Verbesserung der Testspezifität
EP2167965B1 (de) * 2007-06-22 2013-04-10 B.R.A.H.M.S GmbH Verfahren zur detektion von analyten
EP2020603A1 (en) * 2007-08-03 2009-02-04 BRAHMS Aktiengesellschaft Method for risk stratification in stable coronary artery disease
ATE533061T1 (de) * 2007-08-03 2011-11-15 Brahms Gmbh Verfahren zur diagnose bakterieller infektionen
EP2101178A1 (en) * 2008-03-12 2009-09-16 BRAHMS Aktiengesellschaft Use of Procalcitonin (PCT) in prognosis following acute coronary syndromes
GB0722729D0 (en) * 2007-11-20 2007-12-27 Bristol Myers Squibb Co Diagnostic markers of wound infection
ES2601104T3 (es) * 2009-10-13 2017-02-14 B.R.A.H.M.S Gmbh Procalcitonina para el diagnóstico de infecciones bacterianas y la guía del tratamiento antibiótico en pacientes con apoplejía aguda o accidente isquémico transitorio

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993811A (en) * 1997-02-03 1999-11-30 Biology Associates, Llc Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
CN101029897A (zh) * 2007-02-09 2007-09-05 深圳市新产业生物医学工程有限公司 一种降钙素原测试试剂盒及其测试方法
EP2032992B1 (en) * 2007-02-28 2009-08-26 B.R.A.H.M.S. Aktiengesellschaft Method for the selective determination of procalcitonin 1-116 for diagnostic purposes and antibodies and kits for carrying out such a method

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Deficient leucocyte antisedimentation is related to post-stroke infections and outcome;T. Molnar,et al;《J. Clin. Pathol.》;20081231;第61卷;1209-1213 *
Nils G. Morgenthaler,et al.Sensitive immunoluminometric assay for the detection of procalcitonin.《Clinical Chemistry》.2002,第48卷(第5期),
Sensitive immunoluminometric assay for the detection of procalcitonin;Nils G. Morgenthaler,et al;《Clinical Chemistry》;20020531;第48卷(第5期);第788页第25-59行 *
T. Molnar,et al.Deficient leucocyte antisedimentation is related to post-stroke infections and outcome.《J. Clin. Pathol.》.2008,第61卷
陈跃瑜等.降钙素原的克隆、表达及多抗制备.《热带医学杂志》.2007,第07卷(第03期),
降钙素原的克隆、表达及多抗制备;陈跃瑜等;《热带医学杂志》;20070331;第07卷(第03期);第228页第1.2.7-1.2.9节,第229页的讨论部分 *

Also Published As

Publication number Publication date
CN102081101A (zh) 2011-06-01
US20110086831A1 (en) 2011-04-14
EP2320237B1 (en) 2016-08-03
US8383332B2 (en) 2013-02-26
JP2015057611A (ja) 2015-03-26
JP5722587B2 (ja) 2015-05-20
EP2320237A1 (en) 2011-05-11
HK1156690A1 (en) 2012-06-15
ES2601104T3 (es) 2017-02-14
JP2011085586A (ja) 2011-04-28

Similar Documents

Publication Publication Date Title
EP2320237B1 (en) Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with acute stroke or transient ischemic attack
US11241395B2 (en) Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease
CN102257386B (zh) 通过测定标志肽的水平在已患过中风或短暂性缺血性发作的患者中进行预后和风险评估
US11402393B2 (en) Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with non-specific complaints
Kotoula et al. Procalcitonin for the early prediction of renal parenchymal involvement in children with UTI: preliminary results
JP5650718B2 (ja) プロカルシトニンのレベルを測定することによる原発性非感染症疾患に罹患している患者における抗生物質処置のためのリスク評価
Bañuelos-Andrío et al. Usefulness of analytical parameters in the management of pediatric patients with suspicion of acute pyelonephritis. Is procalcitonin reliable?
HK1156690B (en) Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with acute stroke or transient ischemic attack
BOGDAN-DUICĂ THE IMPORTANCE OF THE PARACLINICAL INVESTIGATIONS IN ASSESSING THE PATIENTS WITH CHRONIC DIARRHOEA
HK1145875A (en) Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease
HK1183707B (en) Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1156690

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1156690

Country of ref document: HK